Audiologists in North Myrtle Beach, SC Accepting Medicare
3 Audiologists found. Showing 1 - 3
 Tommi Michelle Gray Stanley, M.S. CCC-A Audiologist Medicare: Medicare Enrolled Practice Location: 1016 2nd Ave N Ste 102, North Myrtle Beach, SC 29582 Phone: 843-732-6090 Fax: 843-491-3573 |
Dr. Kimberly Rae King, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 640 6th Ave S, North Myrtle Beach, SC 29582 Phone: 843-663-4327 Fax: 843-663-3277 |
 Grand Strand Hearing Audiologist Medicare: Medicare Enrolled Practice Location: 1016 2nd Ave N, Suite 102, North Myrtle Beach, SC 29582 Phone: 843-732-6090 Fax: 843-491-3573 |
News Archive
Atheromatosis, which lies behind heart attacks, stroke, and other cardiovascular problems, has a major impact on public health
These two diseases are completely different from each other, but they do have one common denominator: inflammation. Researchers at Lund University in Sweden can now show that it might also be possible to treat them with the same drug.
THC in marijuana may block the spread of forms of cancer causing herpes viruses
The compound in marijuana that produces a high, delta-9 tetrahydrocannbinol or THC, may block the spread of several forms of cancer causing herpes viruses, University of South Florida College of Medicine scientists report.
Altered mindsets: Marijuana is making its mark on ballots in red states
When Tamarack Dispensary opened in the northwestern Montana city of Kalispell in 2009, medical marijuana was legal but still operating on the fringes of the conservative community.
New bowel cancer screening test demonstrates major increase in participation rates
A large pilot study of a new bowel cancer screening test has demonstrated a major increase in participation rates across population groups.
Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
› Verified 7 days ago
Chiropractors
Physical Therapists
Optometrists
Occupational Therapists
Speech-Language Pathologists
Audiologists
Podiatrists